EGFR and ovarian carcinoma: Therefore, in this study we examined the relative expression and cellular location of all members of the HER family, the type-III mutated form of EGFR (EGFRvIII), c-MET, IGF-1R and CD44 by immunohistochemistry in patients with FIGO stage III and IV ovarian cancer and their associations with clinico-pathological parameters, overall survival and disease-free survival.